LoginSignup
profile image
SemiGrowth
@SemiGrowth
6Mon·

$MEDP (+0.09%) Were earnings really that bad? Sales are supposed to be lower, but the bottom line has been raised considerably and the backlog has also grown.

Billings have collapsed, which is probably the reason, but I see a good long-term entry point

3
17 Comments
profile image
Tenbagger2024@Tenbagger2024
6Mon
As far as I know, there are figures on Wednesday.
It is often the case that some investors sell before the figures and get nervous.
Let's wait and see on Wednesday.
At the moment I think the whole market is pretty nervous.
•
2
•
profile image
SemiGrowth@SemiGrowth
6Mon
@Tenbagger2024 Haven't the figures already come out?
•
1
•
profile image
Tenbagger2024@Tenbagger2024
6Mon
••
profile image
Dennis@GordonGekko83
6Mon
@Tenbagger2024 numbers are out!
•
2
•
profile image
Brody@Brody
6Mon
@Tenbagger2024 Do you have an idea? Sell on good news? At first glance, it can't be the figures.
••
profile image
Brody@Brody
6Mon
••
profile image
Memo0606@Memo0606
4Mon
what do you think of medpace's current rating?
••
profile image
SemiGrowth@SemiGrowth
4Mon
@Memo0606 am now in for the long term. I don't think the valuation is too high. MEDP is virtually a shovel manufacturer in an important sector of the future
•
1
•
profile image
Memo0606@Memo0606
4Mon
@SemiGrowth I am on the verge of buying $MRK
••
profile image
SemiGrowth@SemiGrowth
4Mon
@Memo0606 I've just added it to my watchlist, but haven't gotten around to it yet
••
profile image
Memo0606@Memo0606
4Mon
@SemiGrowth is absolutely fair at the moment
and quality company
offers both growth and dividends
my fingers are twitching to get in at the moment
••
profile image
SemiGrowth@SemiGrowth
4Mon
@Memo0606 I just had a look at it, it looks great. I think I'll go in there sometime
••
profile image
Memo0606@Memo0606
4Mon
@SemiGrowth define "mega" from your point of view 😃
••
profile image
SemiGrowth@SemiGrowth
4Mon
@Memo0606 fantastic margins (80 Gross, >30 Net, >20 FCF), favorable in historical comparison. The product positioning in the high-margin segments (animals, cancer) and especially the latter is likely to be a growth market. At the moment, everyone is only looking at Eli Lilly, which is why this could be an anti-cyclical play in the sector. I like how the management handles cash (conservative). Only the relatively high level of debt is a negative point. Sales growth is currently low. But profit and FCF growth is extremely high (due to base effects). The valuation of 13 P/E is quite favorable in my opinion. Oh and Merck is also a long-term runner, compounder or quality stock with a discount
••
profile image
Memo0606@Memo0606
4Mon
@SemiGrowth so are you buying now or are you still waiting or watching?
I just don't want the value to run away from me
••
profile image
SemiGrowth@SemiGrowth
4Mon
@Memo0606 I will probably go in in installments, but I don't know when yet.

You can consider a momentum discount strategy against the "runaway". For example, you buy when it rises/falls above 108 or below 101. Then you either have a low price and if it doesn't fall that low, you're still in. Or you go in in very small tranches. Then you at least have a few shares should it run away from you
•
2
•
profile image
Memo0606@Memo0606
4Mon
@SemiGrowth thanks for the tip, keep us posted on when you buy your 1st installment
•
2
•
Join the conversation
Sign upLogin